Using AI, we identified publications that likely reported a testing or mutation rate, filtered publications for cancer type, and identified sentences that likely reported rates. Rates and covariates ...
NEW YORK (Reuters) - Pfizer is trying to increase doctor awareness of and testing for a rare lung cancer mutation to help boost use of its drug Braftovi, which the pharmaceutical maker anticipates ...
Dec 15 (Reuters) - Biocartis Group Nv : * Biocartis Group: CE-marking Idylla NRAS-BRAF mutation test completes offering of metastatic colorectal cancer tests for clinical use on Idylla platform Source ...
Pivotal results from the Phase 3 BREAKWATER trial showed 51% risk reduction in death compared to standard-of-care treatment BRAFTOVI combination regimen also demonstrated 47% risk reduction in disease ...
The BREAKWATER trial showed significant improvement in progression-free survival with Braftovi, Erbitux, and mFOLFOX6 in mCRC patients with BRAF V600E mutations. Median overall survival was 30.3 ...
Pfizer Inc. (NYSE: PFE) today announced positive results from Cohort 3, a separate randomized cohort of the pivotal BREAKWATER trial, evaluating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback